Aclarion

ACON

Market cap $7.69M

Broomfield, CO, April 16, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S.

Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,” covering its machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data.

Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category.

Expands use of Nociscan in groundbreaking trial Broomfield, CO, April 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine.

Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain BROOMFIELD, Colo.

Stock has declined 99% since its IPO Believes Neal has repeatedly failed to fulfill his fiduciary responsibility Since 2021 Neal has received $240,000 Board compensation Accepted 20% pay increase in 2025 despite the company and shareholders suffering losses Believes Neal lacks appropriate skill set to serve on the Board Despite being on the Board for 9 years, Neal owns only two shares with a total market value of $6.24. Recently further entrenched himself with anti-takeover measures Questions employment of Jeff Thramann Believes Board could easily create meaningful shareholder value Notes stock trades below its net cash NEW YORK, NY / ACCESS Newswire / March 24, 2026 / Earlier today Ephraim Fields of Echo Lake Capital sent a letter to David K.

BROOMFIELD, Colo., March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 Broomfield, CO, March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.